Argenx Fails Phase 3 Trial for Sjögren’s Disease Drug

Argenx reported that its drug Vyvgart failed to outperform placebo in a Phase 3 trial for Sjögren’s disease, leading to a 13% drop in its stock price.

Why it matters. Argenx’s stock and market sentiment in the biotech sector are affected by the failed trial.